



PATENT  
Customer No. 22,852  
Attorney Docket No. 02481.1702

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
Bernward SCHÖLKENS et al. ) Group Art Unit: 1617  
Application No.: 09/645,556 ) Examiner: J. Kim  
Filed: August 25, 2000 )  
For: PHARMACEUTICAL ) Confirmation No.: 3278  
FORMULATIONS AND USE )  
THEREOF IN THE PREVENTION )  
OF STROKE, DIABETES AND/OR )  
CONGESTIVE HEART FAILURE )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached listing. This Supplemental Information Disclosure Statement is being filed concurrently with a Request for Continued Examination.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute "prior art." If the Examiner applies the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.


Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: January 26, 2005

By: 

Steven J. Scott  
Reg. No. 43,911



## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheet

1

8

1

***Complete if Known***

Application Number	09/645,556
Filing Date	August 25, 2000
First Named Inventor	Bernward SCHÖLKENS
Art Unit	1617
Examiner Name	J. Kim
Attorney Docket Number	02481.1702

## **U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS**

**Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004**

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>5</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
		Terri J. Allen et al., "Diabetic Vascular Hypertrophy and Albuminuria: Effect of Angiotensin Converting Enzyme Inhibition," J Diab Comp, vol. 9, pages 318-322, 1995	
		Office Action dated July 29, 2004, from US Patent Application No. 10/694,001	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.